Drug Profile

KSHN 001022

Alternative Names: KSHN-001022

Latest Information Update: 13 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kashiv BioSciences
Class Antineoplastics; Estradiol congeners; Estrenes; Fluorinated hydrocarbons; Sulfoxides
Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Breast cancer

Most Recent Events

10 Aug 2026 Kashiv BioSciences has been acquired by Amneal Pharmaceuticals
21 Jul 2021 KSHN 001022 is available for licensing as of 21 Jul 2021. https://kashivbiosciences.com/company-overview/
04 Jun 2021 Preclinical trials in Breast cancer in India (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com